<DOC>
	<DOCNO>NCT01516541</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , parallel-group study evaluate potential dalcetrapib reduce cardiovascular morbidity mortality patient stable coronary heart disease ( CHD ) , CHD risk equivalent elevate risk cardiovascular disease . Eligible patient randomize receive either dalcetrapib 600 mg orally daily placebo orally daily , background contemporary , guidelines-based medical care . Anticipated time study treatment 4 year .</brief_summary>
	<brief_title>A Study Dalcetrapib Patients With Stable Coronary Heart Disease , With Coronary Heart Disease Risk Equivalents Elevated Risk Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>Adult patient , &gt; /= 45 year age Established cardiovascular disease A stable coronary disease B cerebrovascular disease C peripheral artery disease Without establish coronary disease D pharmacologically treat type 2 diabetes mellitus one risk factor ( ) cardiovascular disease E 3 risk factor cardiovascular disease Receiving evidencebased medical dietary management dyslipidemia Occurrence myocardial infarction , hospitalization unstable angina , stroke revascularization ( coronary , carotid peripheral ) within three month prior randomization Uncontrolled hypertension Uncontrolled diabetes Concomitant treatment drug raise HDLC Previous treatment compound target cholesteryl ester transfer protein ( CETP )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>